Document is current
Any future updates will be listed below
-
Authors
Griffante, Gloria
Gugliesi, Francesca https://orcid.org/0000-0001-6389-5129
Pasquero, Selina
Dell’Oste, Valentina https://orcid.org/0000-0002-9336-7906
Biolatti, Matteo https://orcid.org/0000-0001-7675-0762
Salinger, Ari J.
Mondal, Santanu
Thompson, Paul R. https://orcid.org/0000-0002-1621-3372
Weerapana, Eranthie
Lebbink, Robert J.
Soppe, Jasper A.
Stamminger, Thomas
Girault, Virginie https://orcid.org/0000-0002-3240-4400
Pichlmair, Andreas https://orcid.org/0000-0002-0166-1367
Oroszlán, Gábor https://orcid.org/0000-0003-3798-9097
Coen, Donald M. https://orcid.org/0000-0002-2148-5671
De Andrea, Marco https://orcid.org/0000-0002-3188-5783
Landolfo, Santo https://orcid.org/0000-0002-3153-2865
- License Information
-
More Information
Article History
Received: 7 October 2019
Accepted: 29 May 2021
First Online: 23 June 2021
Competing interests
: The authors declare the following competing financial interest(s): P.R.T. founded Padlock Therapeutics and is entitled to payments from Bristol Myers Squibb if certain milestones are met. P.R.T. is a consultant for Celgene and Disarm Therapeutics. Italian Patent No. 102011596547852 issued in October 20, 2019 (“PAD2 PER USO NELLA PREVENZIONE E/O TRATTAMENTO O DIAGNOSI DI INFEZIONI DA VIRUS DELLA FAMIGLIA HERPESVIRIDAE”).
